Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EPS (Basic) (2023 - 2025)

Contineum Therapeutics has reported EPS (Basic) over the past 3 years, most recently at -$0.49 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.49 for Q4 2025, up 14.04% from a year ago — trailing twelve months through Dec 2025 was -$2.18 (up 55.6% YoY), and the annual figure for FY2025 was -$2.17, changed 0.46%.
  • EPS (Basic) for Q4 2025 was -$0.49 at Contineum Therapeutics, down from -$0.45 in the prior quarter.
  • Over the last five years, EPS (Basic) for CTNM hit a ceiling of $2.56 in Q2 2023 and a floor of -$3.55 in Q1 2024.
  • Median EPS (Basic) over the past 3 years was -$0.55 (2023), compared with a mean of -$0.82.
  • Peak annual rise in EPS (Basic) hit 85.13% in 2024, while the deepest fall reached 115.23% in 2024.
  • Contineum Therapeutics' EPS (Basic) stood at -$0.53 in 2023, then dropped by 7.55% to -$0.57 in 2024, then rose by 14.04% to -$0.49 in 2025.
  • The last three reported values for EPS (Basic) were -$0.49 (Q4 2025), -$0.45 (Q3 2025), and -$0.62 (Q2 2025) per Business Quant data.